CRBU NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Caribou Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 1.57 USD
-4.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -13.2% below the Trend Line and sits at 8.8% of its 52-week range. The latest completed week returned -4.8%, after a -6.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 25 out of 100
Latest Close 1.57 USD 24 Jul 2026
1W Return -4.8% latest completed week
4W Return -6.5% short-term follow-through
12W Return -16.0% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.8% Latest completed week; four-week move -6.5%. Indicator stack 25/30 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 57.3%. News sentiment 59/100 60 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -13.2% below the Trend Line and sits at 8.8% of its 52-week range. The latest completed week returned -4.8%, after a -6.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3612-week average 0.46

12-week confirmation

Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.36Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -6.5% over four weeks, -16.0% over 12 weeks, and -31.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.8%
4W-6.5%
12W-16.0%
26W2.6%
52W-31.1%
Active trend streak0 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.65Latest activity-pressure read.
Pressure change-103.7%Four-week change in activity pressure.
Leadership-24.09Latest relative-leadership reading.
RS change-5.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength5/100Blend of value, momentum, and quality. Underlying universe rank 96; rank 1 is best.
Value28/100Relative valuation strength. Underlying universe rank 73; rank 1 is best.
Quality3/100Profitability and accounting quality. Underlying universe rank 98; rank 1 is best.
Momentum12/100Medium-term price momentum. Underlying universe rank 89; rank 1 is best.
Growth74/100Revenue and earnings growth. Underlying universe rank 27; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
13.9x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-58.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-117.3%
Gross profit retained from each unit of revenue.
Operating margin
-1027.4%
Operating profit retained from revenue.
Free-cash-flow margin
-896.5%
Free cash flow generated from revenue.
Return on invested capital
-73.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
13.0%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-4.0%
Net share repurchases relative to market value.
Shareholder yield
-4.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CRBU shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 3.29, expected move of 57.3%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move57.3%
Put/call volume3.29
Pressure-44
Speculation8
Volatility88
Trend agreement89
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment59/100

Weighted news tone is neutral across 60 relevant articles.

24 positive · 33 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move57.3%Nearest-chain priced movement where available.
52-week drawdown-55.6%Distance below the 52-week high.
13-week volatility10.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+14.0%Week of 17 Apr.
Worst week-18.6%Week of 5 Jun.
Latest week-4.8%Week of 24 Jul.

Shape of recent returns

Strong gains9
Modest gains5
Flat weeks0
Modest losses4
Sharp losses8
Recent vol10.2%13-week weekly-return volatility.
Base vol9.3%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew7.8% / -7.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape26/100

Trend, activity pressure, participation, and risk combine to a 26/100 tape read.

 Indicator analysis37/100

Latest 12-week confirmation: trend 4/12, activity pressure 7/12, relative leadership 1/12.

Activity pressure 0.36; No reversal markers Factors10/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 81; Small Cap Core rank 79 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options61/100

CRBU shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 3.29, expected move of 57.3%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 57.3% Sentiment59/100

Weighted news tone is neutral across 60 relevant articles.

Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20261.57 USD-4.8%1.81 USD2.73 USD-0.65-24.095.5MOff
17 Jul 20261.65 USD-14.3%1.81 USD2.76 USD-0.44-22.3610.4MOff
10 Jul 20261.93 USD5.8%1.81 USD2.80 USD-0.46-13.8913.0MOff
3 Jul 20261.82 USD8.3%1.81 USD2.82 USD-0.55-17.267.8MOff
26 Jun 20261.68 USD2.4%1.81 USD2.86 USD-0.32-22.9321.2MOff
19 Jun 20261.64 USD2.8%1.82 USD2.87 USD0.09-28.128.1MOff
12 Jun 20261.59 USD-16.9%1.82 USD2.89 USD0.56-28.379.3MOn
5 Jun 20261.92 USD-18.6%1.84 USD2.91 USD1.01-11.749.3MOn
29 May 20262.36 USD12.4%1.84 USD2.92 USD1.073.828.6MOn
22 May 20262.10 USD-1.9%1.85 USD2.94 USD0.86-4.258.3MOn
15 May 20262.14 USD10.3%1.86 USD2.95 USD0.88-0.6710.7MOff
8 May 20261.94 USD3.7%1.87 USD2.97 USD0.84-9.555.8MOff
1 May 20261.87 USD-12.2%1.89 USD2.98 USD0.84-7.356.7MOff
24 Apr 20262.13 USD-3.2%1.91 USD3.00 USD0.877.838.7MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.